Table 5.
Representative list of anticancer siRNA-mediated nanoparticles in clinical trials.
| Therapeutic Name | Delivery System | Type of Cancer | Status | Reference |
|---|---|---|---|---|
| NBF-006 | Lipid nanoparticles | Non-small cell lung carcinoma, pancreatic carcinoma, colorectal carcinoma | Phase I/recruiting | [237] |
| siRNA-EphA2- DOPC |
Lipid nanoparticles | Advanced cancers | Phase I/Not completed yet |
[238] |
| ALN-VSP02 | Lipid nanoparticles | Solid liver tumors | Phase I/Completed |
[239] |
| siG12D LODER | LODER polymer | Pancreatic cancer, pancreatic ductal Adenocarcinoma |
Phase II/Ongoing |
[240] |
| Atu027 | Lipid nanoparticles | Metastatic pancreatic cancer (II), solid tumors (I) |
Phase II/Completed |
[241] |
| TKM- PLK1 (TKM-080301) |
Lipid nanoparticles | Hepatocellular carcinoma (II), adrenal cortical carcinoma (II), neuroendocrine tumor (II), solid tumors (I) | Phase II/Completed |
[209] |